Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Gardner

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Hepatology (Baltimore, Md.)|April 2, 2003
Durability of serologic response after lamivudine treatment of chronic hepatitis BJules L Dienstag, Janusz Cianciara, Selim Karayalcin, et al.
Clinical Therapeutics|January 1, 2013
Pharmacokinetic properties of single-dose lamivudine/adefovir dipivoxil fixed-dose combination in healthy Chinese male volunteersBenny S P Fok, Stephen Gardner, Steve Piscitelli, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 23, 2020
A multi-institutional assessment of COVID-19-related risk in radiation oncologyNatalie Viscariello, Suzanne Evans, Stephanie Parker, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|October 22, 2016
Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapyMorten A Karsdal, Kim Henriksen, Mette Juul Nielsen, et al.
Gastroenterology|January 4, 2003
Histological outcome during long-term lamivudine therapyJules L Dienstag, Robert D Goldin, E Jenny Heathcote, et al.
Gastroenterology|December 31, 2003
Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virusRobert Perrillo, Hie-Won Hann, David Mutimer, et al.
Journal of Clinical Pharmacology|April 11, 2015
Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845 (GSK2336805) in subjects with hepatic impairmentKimberly K Adkison, Jianjun Gan, Lucinda Elko-Simms, et al.
Gastroenterology|December 17, 2009
Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infectionJohn McHutchison, Zachary Goodman, Keyur Patel, et al.
Practical Radiation Oncology|February 16, 2017
Development of a model web-based system to support a statewide quality consortium in radiation oncologyJean M Moran, Mary Feng, Lisa A Benedetti, et al.
Journal of Applied Clinical Medical Physics|July 29, 2015
Characteristics of a novel treatment system for linear accelerator-based stereotactic radiosurgeryNing Wen, Haisen Li, Kwang Song, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Hepatology (Baltimore, Md.)|April 2, 2003
Durability of serologic response after lamivudine treatment of chronic hepatitis BJules L Dienstag, Janusz Cianciara, Selim Karayalcin, et al.
Clinical Therapeutics|January 1, 2013
Pharmacokinetic properties of single-dose lamivudine/adefovir dipivoxil fixed-dose combination in healthy Chinese male volunteersBenny S P Fok, Stephen Gardner, Steve Piscitelli, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 23, 2020
A multi-institutional assessment of COVID-19-related risk in radiation oncologyNatalie Viscariello, Suzanne Evans, Stephanie Parker, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|October 22, 2016
Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapyMorten A Karsdal, Kim Henriksen, Mette Juul Nielsen, et al.
Gastroenterology|January 4, 2003
Histological outcome during long-term lamivudine therapyJules L Dienstag, Robert D Goldin, E Jenny Heathcote, et al.
Gastroenterology|December 31, 2003
Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virusRobert Perrillo, Hie-Won Hann, David Mutimer, et al.
Journal of Clinical Pharmacology|April 11, 2015
Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845 (GSK2336805) in subjects with hepatic impairmentKimberly K Adkison, Jianjun Gan, Lucinda Elko-Simms, et al.
Gastroenterology|December 17, 2009
Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infectionJohn McHutchison, Zachary Goodman, Keyur Patel, et al.
Practical Radiation Oncology|February 16, 2017
Development of a model web-based system to support a statewide quality consortium in radiation oncologyJean M Moran, Mary Feng, Lisa A Benedetti, et al.
Journal of Applied Clinical Medical Physics|July 29, 2015
Characteristics of a novel treatment system for linear accelerator-based stereotactic radiosurgeryNing Wen, Haisen Li, Kwang Song, et al.
Pageof 3